【摘要】 背景与目的易瑞沙(Iressa)是小分子表皮生长因子受体酪氨酸激酶抑制剂,主要用于治疗晚期非小细胞肺癌(NSCLC)。本研究探讨易瑞沙单药治疗化疗后进展的晚期非小细胞肺癌的疗效与不良反应。方法24例化疗后进展的晚期NSCLC患者接受治疗,其中二线以上治疗后进展者占62.5%。易瑞沙250mg口服,每日1次,服用至疾病进展或出现不可耐受的不良反应。治疗后每4周复查一次,16周后每8周复查一次。结果本组24例患者均可评价疗效。其中完全缓解1例,部分缓解8例,无变化3例,进展12例。有效率为37.5%,稳定率为12.5%,临床获益率为50.0%,中位肿瘤进展时间为87天。随访2年,1和2年生存率分别为33.3%和12.5%。常见不良反应为Ⅰ、Ⅱ度皮肤改变和腹泻,未发生Ⅲ度以上不良反应。有2例患者因怀疑发生肺部间质性改变而结束治疗。结论易瑞沙治疗化疗后进展的晚期NSCLC的疗效显著,不良反应轻,是晚期NSCLC患者二、三线用药的最佳选择之一。更多还原

【Abstract】 Background and objective Iressa is the inhibitor of epidemic growth factor receptor and mainly used to treat non-small cell lung cancer (NSCLC). The aim of this study is to evaluate the antitumor efficacy and toxicity of Iressa in the treatment of advanced NSCLC patients who had failed to previous chemotherapy. Methods Twenty-four patiets with advanced NSCLC who were previously treated with chemotherapy received 250mg of Iressa orally once daily until disease progressing or intolerable toxicity developing. Tumor evaluation was performed before treatment. Then for every four weeks after administration they recevied the examination; after administration for sixteen weeks, examination was repeated once every eight weeks. Results All twenty-four patients could be evaluated. One case got complete response, eight cases got partial response, three had no change and twelve had disease progression. So the response rate was 37.5%, the stable disease rate was 12.5%, and the clinical benifit rate was 50.0%. Median time to disease progressing was 87 days. All patients were followed up for two years and 1- and 2-year survival rate was 33.3% and 12.5% respectively. The common adverse effects were skin reaction and diarrhea and no grade Ⅲ or Ⅳ toxicity was observed. Two cases were suspected of pulmonary interstitial changes and the treatment ended. Conclusion Iressa is effective in treatment of advanced NSCLC patients who had failed to previous chemotherapy and the adverse effects are tolerable. So Iressa is one of the best choice for NSCLC patients who need two or more line therapy.更多还原